Citizens & Northern Corp Increases Holdings in Pfizer Inc. (NYSE:PFE)

Citizens & Northern Corp grew its stake in Pfizer Inc. (NYSE:PFE) by 7.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,646 shares of the biopharmaceutical company’s stock after acquiring an additional 2,545 shares during the quarter. Citizens & Northern Corp’s holdings in Pfizer were worth $972,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of PFE. CIBC Asset Management Inc raised its position in shares of Pfizer by 0.3% during the 4th quarter. CIBC Asset Management Inc now owns 1,068,039 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 2,701 shares during the period. Pittenger & Anderson Inc. increased its stake in Pfizer by 9,571.7% during the fourth quarter. Pittenger & Anderson Inc. now owns 102,520 shares of the biopharmaceutical company’s stock worth $2,720,000 after acquiring an additional 101,460 shares during the last quarter. Cutler Investment Counsel LLC purchased a new stake in Pfizer in the fourth quarter valued at $4,687,000. Human Investing LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $85,000. Finally, KLCM Advisors Inc. grew its holdings in shares of Pfizer by 44.0% during the 4th quarter. KLCM Advisors Inc. now owns 189,694 shares of the biopharmaceutical company’s stock worth $5,033,000 after purchasing an additional 57,984 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.6 %

NYSE PFE opened at $25.50 on Tuesday. The stock has a market capitalization of $144.48 billion, a PE ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The firm has a 50 day moving average of $26.28 and a two-hundred day moving average of $27.54. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same period last year, the firm earned $0.10 earnings per share. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a yield of 6.75%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio is currently 121.99%.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.06% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Guggenheim reaffirmed a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research note on Monday, February 10th. Finally, UBS Group decreased their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.